Nosocomial SBP has a poorer outcome than community-acquired SBP. The resistance to third-generation cephalosporins for gram-negative organisms, which are more common in nosocomial cases of SBP than in community-acquired cases of SBP, adversely affects the outcome of SBP in patients with liver cirrhosis.

BackgroundDue to limited therapeutic options, the spread of extended-spectrum beta-lactamases (ESBLs) have become a major public health concern. We conducted a prospective, randomized, open-label comparison of the therapeutic efficacy of piperacillin-tazobactam (PTZ), cefepime, and ertapenem in febrile nosocomial urinary tract infection with ESBL-producing Escherichia coli (ESBL-EC).MethodsThis study was conducted at three university hospitals between January 2013 and August 2015. Hospitalized adult patients presenting with fever were screened for healthcare-associated urinary tract infection (HA-UTI). When ESBL-EC was solely detected and susceptible to a randomized antibiotic in vitro, the case was included in the final analysis. Participants were treated for 10–14 days with PTZ, cefepime, or ertapenem.ResultsA total of 66 participants were evenly assigned to the PTZ and ertapenem treatment groups. After the recruitment of six participants, assignment to the cefepime treatment group was stopped because of an unexpectedly high treatment failure rate. The baseline characteristics of these participants did not differ from participants in other treatment groups. The clinical and microbiological response to PTZ treatment was estimated to be 94% and was similar to the response to ertapenem treatment. The efficacy of cefepime was 33.3%. In the cefepime group, age, Charlson comorbidity index, genotype, and minimal inhibitory concentration (MIC) did not significantly affect the success of treatment. Similarly, genotype seemed to be irrelevant with respect to clinical outcome in the PTZ group. Expired cases tended to involve septic shock with a high Charlson comorbidity index and high MIC.ConclusionResults from this study suggest that PTZ is effective in the treatment of urinary tract infection caused by ESBL-EC when the in vitro test indicates susceptibility. In addition, cefepime should not be used as an alternative treatment for urinary tract infection caused by ESBL-EC.Trial registrationThe trial was registered with the Clinical Research Information Service of Korea Centers for Disease Control and Prevention. (KCT0001895)

BACKGROUND: A considerable number of patients with dilated cardiomyopathy (DCM) experience left ventricular reverse remodeling (LVRR). LV global longitudinal strain (LV GLS) offers sensitive and reproducible measurement of myocardial dysfunction. The authors sought to evaluate whether LV GLS at the time of diagnosis may predict LVRR in DCM patients with sinus rhythm and investigate its prognostic role in long-term follow-up in this population. METHODS: We enrolled 160 DCM patients with sinus rhythm who had been initially diagnosed, evaluated, and followed at our institute. We analyzed their medical records and echocardiographic data. RESULTS: During the mean follow-up duration of 37.3 ± 21.7 months, LVRR occurred in 28% of patients (n = 45). The initial LV ejection fraction (LVEF) of patients who recovered LV function was 26.1 ± 7.9%, which was not significantly different from the value of 27.1 ± 7.4% (p = 0.49) in those who did not recover. There was a moderate and highly significant correlation between baseline LV GLS (−%) and follow-up LVEF (r = 0.717; p < 0.001). Using multivariate Cox analysis, LV GLS (hazard ratio: 1.474, 95% confidence interval: 1.170-1.856; p = 0.001) was an independent predictor of LVRR. CONCLUSIONS: We demonstrated that LV GLS was an independent predictor for LVRR and the optimal cutoff point of LV GLS for LVRR was −10% in DCM patients with sinus rhythm. There was a significant correlation between baseline LV GLS and follow-up LVEF.

Background: To date, no consensus has been reached regarding validated and practical tools to quantify the severity of hemifacial spasm (HFS) before and after surgery. Objective: The aim of this study has been to establish objective parameters for determining the preoperative severity of HFS and to assess the correlation with quality of life (QoL) in HFS patients. Methods: Patients who experienced HFS between April and August 2010 were reviewed. The patients were divided into four groups according to the severity of spasm (SMC grade): grade I – localized spasm around the periocular area; grade II – involuntary movement spreads to other parts of the ipsilateral face and it affects other muscle groups, i.e. the orbicularis oris, zygomaticus, frontalis or platysma muscle; grade III – interference with vision because of frequent tonic spasms, and grade IV – disfiguring asymmetry. We interviewed each patient using an HFS-7 questionnaire containing a short self-rating QoL scale. We estimated the measure of agreement across observers and examined the relationships between SMC grade and other factors, including HFS-7 responses. Results: Preoperative evaluation using the SMC grading system showed 25 patients with grade I, 48 patients with grade II, 33 patients with grade III, and 12 patients with grade IV HFS. The HFS-7 scores indicating QoL were 9 (range: 0–17) in grade I, 12 (range: 1–25) in grade II, 16 (range: 2–23) in grade III, and 17 (range: 3–24) in grade IV subjects. SMC grade was correlated with symptom duration (p < 0.0001) and HFS-7 score (p = 0.02). In addition, higher SMC grade was closely associated with longer duration of persisting symptoms (p < 0.05). Conclusions: An SMC grading system is useful as a means of quantifying spasms to allow for more precise descriptions of a patient’s condition including QoL, and to improve the accuracy of communication between medical teams.